Skip to main content

Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality

Psychopharmacology volume 192, pages 61–70 (2007)Cite this article

Abstract

Rationale

Manipulations of the endocannabinoid/fatty acid amide hydrolase (FAAH) signaling systems result in conflicting and paradoxical effects in rodent models of emotional reactivity.

Objectives

In the present study, we tested the hypothesis that the inhibition of FAAH would elicit significant effects in murine models used to screen anxiolytic and antidepressant drugs.

Materials and methods

FAAH (−/−) mice and wild-type mice treated with FAAH inhibitors (URB597 and OL-135) were evaluated in standard behavioral screening models for antidepressant (i.e., tail suspension and forced-swim tests) and anxiolytic (i.e., elevated plus maze) agents. The doses of URB597 and OL-135 selected were based on their ability to augment the pharmacological effects (i.e., analgesia, catalepsy, and hypothermia) of exogenously administered anandamide.

Results

FAAH (−/−) mice, anandamide-injected FAAH (−/−) mice, or wild-type mice injected with FAAH inhibitors or anandamide failed to exhibit significant effects in standard tests of emotional reactivity, although the antidepressant desipramine and the anxiolytic agent midazolam were active in the appropriate assays. FAAH- (−/−) and URB597-treated mice finally displayed significant effects in the tail suspension test when substantial methodological changes were made (i.e., altered ambient light and increased sample sizes).

Conclusions

Although FAAH suppression can elicit significant effects under some instances in which consequential procedural modifications are made, the present results indicate that the pharmacological inhibition or genetic deletion of FAAH is ineffective in standard mouse models of emotional reactivity. It remains to be established whether the effects of FAAH inhibition in these modified tasks are predictive of their efficacy in treating emotional disorders.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  • Akinshola BE, Chakrabarti A, Onaivi ES (1999) In-vitro and in-vivo action of cannabinoids. Neurochem Res 24:1233–1240

    PubMed  Article  CAS  Google Scholar 

  • Alexander JP, Cravatt BF (2005) Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12:1179–1187

    PubMed  Article  CAS  Google Scholar 

  • Arevalo C, de Miguel R, Hernandez-Tristan R (2001) Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70:123–131

    PubMed  Article  CAS  Google Scholar 

  • Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimaraes CR, Jorgensen WL, Cravatt BF (2005) Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48:1849–1856

    PubMed  Article  CAS  Google Scholar 

  • Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, La Rana G, Russo R, Calignano A, Gessa GL, Cuomo V, Piomelli D (2006) Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31(12):2652–2659

    PubMed  Article  CAS  Google Scholar 

  • Colquhoun D (1997) Lectures on biostatistics: an introduction to statistics with applications in biology and medicine. Clarendon Press, Oxford, pp 327–332

    Google Scholar 

  • Cravatt B, Prospero-Garcia O, Siuzdak G, Gilula N, Henriksen S, Boger D, Lerner R (1995) Chemical characterization of a family of brain lipids that induce sleep. Science 268:1506–1509

    PubMed  Article  CAS  Google Scholar 

  • Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371–9376

    PubMed  Article  CAS  Google Scholar 

  • Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH (2004) Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 101:10821–10826

    PubMed  Article  CAS  Google Scholar 

  • Crawley J, Corwin R, Robinson J, Felder C, Devane W, Axelrod J (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46(4):967–972

    PubMed  Article  CAS  Google Scholar 

  • Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121–2134

    PubMed  Article  CAS  Google Scholar 

  • Fabre LF, McLendon D (1981) The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 21:377S–382S

    PubMed  CAS  Google Scholar 

  • Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352–358

    PubMed  Article  CAS  Google Scholar 

  • Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231:313–314

    PubMed  Article  CAS  Google Scholar 

  • Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620–18625

    PubMed  Article  CAS  Google Scholar 

  • Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261–267

    PubMed  Article  CAS  Google Scholar 

  • Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395–1398

    PubMed  Article  CAS  Google Scholar 

  • Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1–20

    PubMed  CAS  Google Scholar 

  • Holt S, Comelli F, Costa B, Fowler CJ (2005) Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146:467–476

    PubMed  Article  CAS  Google Scholar 

  • Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, Rana GL, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81

    PubMed  Article  CAS  Google Scholar 

  • Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF (2004a) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441–448

    PubMed  Article  CAS  Google Scholar 

  • Lichtman AH, Shelton CC, Advani T, Cravatt BF (2004b) Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109:319–327

    PubMed  Article  CAS  Google Scholar 

  • Maccarrone M, Valverde O, Barbaccia ML, Castane A, Maldonado R, Ledent C, Parmentier M, Finazzi-Agro A (2002) Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci 15:1178–1186

    PubMed  Article  Google Scholar 

  • Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379–387

    Article  CAS  Google Scholar 

  • Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodriguez de Fonseca F (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491–496

    PubMed  Article  CAS  Google Scholar 

  • Nielsen DM, Carey GJ, Gold LH (2004) Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499:135–146

    PubMed  Article  CAS  Google Scholar 

  • Nunes-de-Souza RL, Canto-de-Souza A, da-Costa M, Fornari RV, Graeff FG, Pela IR (2000) Anxiety-induced antinociception in mice: effects of systemic and intra-amygdala administration of 8-OH-DPAT and midazolam. Psychopharmacology (Berl) 150:300–310

    Article  CAS  Google Scholar 

  • Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002–1009

    PubMed  CAS  Google Scholar 

  • Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318(1):304–311

    PubMed  Article  CAS  Google Scholar 

  • Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336

    PubMed  CAS  Google Scholar 

  • Rodgers RJ, Evans PM, Murphy A (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16:405–413

    PubMed  Article  CAS  Google Scholar 

  • Rodgers RJ, Haller J, Halasz J, Mikics E (2003) ‘One-trial sensitization’ to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 17:1279–1286

    PubMed  Article  CAS  Google Scholar 

  • Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob G, Navarro M (1996) Corticotropin-releasing factor (crf) antagonist [D-Phe12, Nle21,38, CaMeLeu37]. J Pharmacol Exp Ther 276:56–64

    PubMed  CAS  Google Scholar 

  • Rutkowska M, Jamontt J, Gliniak H (2006) Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 58:200–206

    PubMed  CAS  Google Scholar 

  • Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 14:573–582

    PubMed  Article  CAS  Google Scholar 

  • Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, Porsolt RD (1987) The automated tail suspension test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 11:659–671

    PubMed  Article  CAS  Google Scholar 

  • Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544–553

    PubMed  Article  CAS  Google Scholar 

  • Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R (2002) Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135:564–578

    PubMed  Article  CAS  Google Scholar 

  • Valverde O, Karsak M, Zimmer A (2005) Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 117–145

  • Varvel SA, Cravatt BF, Engram AE, Lichtman AH (2006) Fatty acid amide hydrolase (−/−) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J Pharmacol Exp Ther 317:251–257

    PubMed  Article  CAS  Google Scholar 

  • Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331–342

    PubMed  Article  CAS  Google Scholar 

  • Wiley JL, Martin BR (2003) Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471:185–193

    PubMed  Article  CAS  Google Scholar 

  • Willoughby KA, Moore SF, Martin BR, Ellis EF (1997) The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282:243–247

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors thank Dr. Lisa Gold for her constructive comments on an earlier version of this manuscript, as well as Dr. Marco Bortolato, Dr. Cecilia Hillard, Dr. Sachin Patel, and Dr. Danielle Piomelli for their professionalism and cooperation. This work was supported by the National Institute on Drug Abuse (DA15197, DA017259, DA015683, and DA005274) and Pfizer.

Author information

Affiliations

  1. Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, 23298-0613, USA

    Pattipati S. Naidu, Stephen A. Varvel, Billy R. Martin & Aron H. Lichtman

  2. Pfizer Global Research and Development, Molecular Pharmacology, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA

    Kyunghye Ahn

  3. The Skaggs Institute for Chemical Biology and Departments of Cell Biology and Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Rd, La Jolla, CA, 92037, USA

    Benjamin F. Cravatt

Authors
  1. Pattipati S. Naidu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen A. Varvel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyunghye Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benjamin F. Cravatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Billy R. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aron H. Lichtman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aron H. Lichtman.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Naidu, P.S., Varvel, S.A., Ahn, K. et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 192, 61–70 (2007). https://doi.org/10.1007/s00213-006-0689-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-006-0689-4

Keywords

  • Antidepressant
  • Anandamide
  • Emotion
  • Depression
  • Cannabinoids
  • Anxiolytic
  • Anxiety
  • Fatty acid amide hydrolase
  • URB597
  • OL135